ONCOmmunity

Real Clinical Practice in ALK-rearranged NSCLC Patients: A Retrospective Observational Study.

By: Shinichiro Okauchi, Takeshi Numata, Takeshi Nawa, Hideo Ichimura, Takefumi Saito, Kenji Hayashihara, Hideyasu Yamada, Hiroaki Satoh, Takeshi Endo, Yoshihisa Inage, Takayuki Kaburagi, Moriyuki Kiyoshima, Yutaka Yamada, Tomohiro Tamura, Kazuhito Saito, Masaharu Inagaki, Nobuyuki Hizawa, Yukio Sato, Toshihiro Shiozawa, Ikuo Sekine, Hiroichi Ishikawa, Koichi Kurihima, Mitsuaki Sakai, Koichi Kamiyama, Masaki Kimura, Norihiro Kikuchi, Hiroyuki Nakamura, Kinya Furukawa, Takahide Kodama, Kunihiko Miyazaki, Takaaki Yamashita, Shigen Hayashi, Yasunori Funayama, Akihiro Nomura

Division of Respiratory Medicine, Mito Kyodo General Hospital-Mito Medical Center, University of Tsukuba, Mito, Japan.
2019-12-01; doi: 10.21873/anticanres.14029

Abstract

Background/aim

To describe real clinical outcomes when using systemic therapy to treat non-small cell lung cancer (NSCLC) patients who have anaplastic lymphoma kinase (ALK) fusion gene mutation.

Patients

We performed a retrospective chart review from April 2008 to March 2019 sourced from 16 medical institutes that cover a population of three million people.

Results

There were 129 ALK rearranged NSCLC patients. Among them, 103 patients including 40 recurrent disease cases received ALK-tyrosine kinase inhibitors (TKI) and chemotherapy. Our treatment results were comparable to previously reported clinical trials and clinical practice studies. First-line alectinib, treatment sequence of ALK-TKI followed by another ALK-TKI, and pemetrexed-containing chemotherapy contributed to the outcome of treatment.

Conclusion

By arrangement of treatment such as treatment sequence of ALK-TKI and chemotherapy regimen, it might be possible to obtain a treatment outcome almost equivalent to those of clinical trials even in real clinical practice.